Key clinical point: Eptinezumab vs placebo significantly reduced the number of headache days with acute headache medication (AHM) use in patients with chronic migraine (CM), with the effect being greatest among those with medication-overuse headache and ≥50% response.
Major finding: Eptinezumab vs placebo resulted in a greater percentage-point reductions in the number of headache days with AHM use in the overall cohort of patients with CM (percentage-point reduction −25.1% vs −17.0%) and in patients with CM and medication-overuse headache who experienced ≥50% response (percentage-point reduction −38.3% vs −31.5%) over 24 weeks.
Study details: Findings are from a post hoc analysis of a phase 3 study, PROMISE-2, including 1072 patients with CM, of which 40.2% were diagnosed with medication-overuse headache and were randomly assigned to receive eptinezumab (100 or 300 mg) or placebo.
Disclosures: This study was funded by Lundbeck Seattle BioPharmaceuticals, Inc., USA. Four authors declared being current or former employees of Lundbeck or a subsidiary company or a company contracted by Lundbeck or owning stocks or stock options in Alder/Lundbeck. Several authors reported ties with Lundbeck or other sources.
Source: Cowan RP et al. Quantity changes in acute headache medication use among patients with chronic migraine treated with eptinezumab: Subanalysis of the PROMISE ‑2 study. J Headache Pain . 2022;23:115 (Sep 6). Doi: 10.1186/s10194-022-01482-0